

Dear Prescriber:

Enclosed are your POMALYST REMS® program education materials

Celgene Corporation is pleased to provide you with the enclosed materials for use in the POMALYST REMS® program.

Important Information about the POMALYST REMS® program

- To avoid embryo-fetal exposure, POMALYST® (pomalidomide) is only available under a restricted distribution program called “POMALYST REMS®”
- Pomalidomide is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with pomalidomide provided adequate precautions are taken to avoid pregnancy
- Male Patients: Clinical data has demonstrated the presence of pomalidomide in human semen. Male patients taking POMALYST should not donate sperm. Males receiving POMALYST must always use a latex or synthetic condom during any sexual contact with females of reproductive potential even if they have undergone a successful vasectomy
- Only prescribers and pharmacies certified with POMALYST REMS® can prescribe and dispense POMALYST to patients who are enrolled and meet all the conditions of the POMALYST REMS® program

As a prescriber certified with the POMALYST REMS® program, please review and familiarize yourself with the contents of the enclosed POMALYST REMS® Kit:

Prescriber Materials

- POMALYST REMS® software and Installation Guide
- Prescriber Guide to POMALYST REMS® Program
- POMALYST Full Prescribing Information

Patient Materials (Patient Resource Pack)

- Patient Guide to POMALYST REMS® Program
- Emergency Contraception Brochure
- MEDICATION GUIDE

To order additional Patient Resource Packs, or if you have any questions about using the enclosed software, please call the Celgene Customer Care Center at 1-888-423-5436.

Sincerely,

Jerome B. Zeldis, MD, PhD

Chief Medical Officer

Enclosures

Risks of POMALYST® (pomalidomide)

- POMALYST is similar to the medicine thalidomide (THALOMID®). Thalidomide can cause severe life-threatening birth defects. If POMALYST is used during pregnancy, it can cause birth defects or embryo-fetal death. POMALYST must not be used by pregnant females and females who are able to get pregnant. Females who are able to get pregnant must avoid pregnancy while taking POMALYST
- Blood clots in your arteries (heart attacks and strokes), veins (deep vein thrombosis) and lungs (pulmonary embolism) can happen if you take POMALYST

POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.

[[Celgene logo]] [[POMALYST REMS® logo]] [[POMALYST logo]]

POMALYST® is a registered trademark of Celgene Corporation. POMALYST REMS® is a trademark of Celgene Corporation.

© 2016 Celgene Corporation

6/16

REMS-POM16743